Caspase inhibition mitigates tau cleavage and neurotoxicity in iPSC‐induced neurons with the V337M MAPT mutation
| Autor: | Michelle R. Arkin, Dulce Ovando Morales, Bruce L. Miller, Celeste M. Karch, Sally Temple, Rakez Kayed, Brian Chin, Shireen Khan, Cathrine Petersen, Panos Theofilas, Raymond T. Ng, Teddy Yang, Lea T. Grinberg, Li Gan, Jason E. Gestwicki, Chao Wang, David Butler |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Mutation
biology Epidemiology Health Policy Neurotoxicity Frontotemporal lobar degeneration medicine.disease medicine.disease_cause Cell biology Pathogenesis Psychiatry and Mental health Cellular and Molecular Neuroscience Developmental Neuroscience mental disorders biology.protein medicine Tauopathy Neurology (clinical) Alzheimer's disease Geriatrics and Gerontology Caspase Frontotemporal dementia |
| Zdroj: | Alzheimer's & Dementia. 17 |
| ISSN: | 1552-5279 1552-5260 |
| Popis: | Tau post-translational modifications (PTMs) are associated with progressive tau accumulation and neuronal loss in tauopathies, including forms of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD). Proteolytic cleavage of tau by active caspases, including caspase-6, represents an underexplored tau PTM implicated in tau pathology. Caspase-cleaved tau is toxic and prone to self-aggregation in experimental models. To elucidate the presence and temporal course of caspase activation, tau cleavage, and neuronal death, we generated two neoepitope monoclonal antibodies (mAbs) against caspase-6 tau proteolytic sites and cortical neurons from induced pluripotent stem cells (iPSCs) with the frontotemporal dementia (FTD)-causing V337M MAPT mutation. FTLD V337M MAPT and AD postmortem brains showed positivity for both cleaved tau mAbs as well as active caspase-6. Relative to isogenic wild-type MAPT controls, V337M MAPT neurons showed a time-dependent increase in pathogenic tau in the form of tau oligomers, caspase-cleaved tau, and p-tau. Accumulation of toxic tau species in 3-month V337M MAPT neurons also increased vulnerability to stress, which was pharmacologically rescued by caspase inhibition. We propose a model in which time-dependent accumulation of caspase-cleaved tau in V337M MAPT neurons promotes neurotoxicity that is reversed by caspase-6 inhibition. Caspase-cleaved tau may be a biomarker of tauopathy, and caspases could be viable targets for therapeutic intervention against tau pathogenesis in FTLD and other tauopathies.SignificanceThe mechanisms leading to tau pathology in frontotemporal dementia (FTD) and Alzheimer’s disease (AD) remain elusive. Experimental studies in AD demonstrate that tau cleavage by active caspase-6 contributes to tau pathology since cleaved tau may be toxic and prone to self-aggregation. Yet, the role of caspase-cleaved tau in promoting toxicity and cell death is unclear. Here, we generated two neoepitope monoclonal antibodies against caspase-6 tau and evaluated tau cleavage in postmortem human brains, iPSC-induced cortical neurons with the FTD-causing V337M MAPT mutation, and isogenic wild-type MAPT controls. Our results demonstrate a time-dependent accumulation of caspase-cleaved tau and increased neurotoxicity in the mutant iNs that is reversed by caspase-6 inhibition. Caspases could be viable therapeutic targets against tau pathology in tauopathies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|